Q-omics provides the consensus-scored MGAT3 profile across patient tissues and cancer cell-line models. MGAT3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MGAT3 is differentially expressed in 16, with the highest sampling consensus in THCA. Additionally, MGAT3 RNA expression shows 19,605 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, THCA, and GBM as cancer lineages where MGAT3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MGAT3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MGAT3 survival associations across molecular data types. MGAT3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MGAT3 RNA expression–survival associations across cancer types. High MGAT3 expression shows unfavorable associations in KIRP and UVM, but favorable associations in HNSC, LGG, SCLC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MGAT3 RNA expression.
This table summarizes MGAT3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MGAT3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MGAT3 shows lower tumor expression in KICH, LUAD and KIRP and higher tumor expression in THCA, LIHC and KIRC. The THCA box plot shows higher MGAT3 RNA expression in tumor versus normal tissue (log2 FC = +3.999, t-test p < 0.001).
This table shows molecular features associated with MGAT3 in patient tissues and cancer cell lines. In patient samples, MGAT3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MGAT3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
